Tellgen Corporation researches and develops, manufactures, and distributes IVDs in China and internationally. The company offers tumor markers; cervical cancer...
Tellgen released its performance for the first three quarters, with a net profit attributable to the parent company of 5.7749 million yuan, a decrease of 76.33%
Tellgen: Completed the repurchase of 737,000 shares
Tellgen: First repurchase of 0.13% of the company's shares
Tellgen: Net profit of 2.7593 million yuan in the first half of 2025, a year-on-year decrease of 58.41%
The gene sequencing sector surged in the short term, and Berry Genomics hit the limit up
Tellgen's subsidiary Jiangxi Tellgen has obtained two medical device registration certificates